CNS Diseases & Hemostasis Overview
QRxPharma has also extended its Central Nervous System (CNS) product portfolio into neurological disorders with an exclusive license to technology from the University of Alabama on the modulation of Torsin, a key protein in the brain. Many neurological diseases, including Parkinson’s, dystonias, Huntington’s, Amytrophic Lateral Sclerosis (ALS) and Alzheimer’s involve the toxic effects of misfolded proteins. While there are no cures for these diseases of the brain, over the past decade significant advances have been made in understanding the molecular and cellular biology of Parkinson’s and dystonia. QRxPharma’s research has identified TorsinA activator drugs that fix misfolded proteins leading to neuroprotection in a range of in vivo models. These discoveries have pointed to the potential for new therapeutics that treat the root cause of such neurodegenerative disorders and not simply the effects of disease. Support for these discoveries at the University of Alabama is provided by the Michael J. Fox Foundation, the Bachmann Strauss Foundation, the Dystonia Medical Research Foundation, the NIH and QRxPharma.
Supported through R&D grants from the Australian government, QRxPharma and the University of Queensland are also developing the use of snake venom components as pro-coagulants for the treatment of patients following surgery, acute hemorrhage and bleeding disorders.